levodopa has been researched along with arachidonic acid in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abdeen, S; Chapman, E; Chitre, S; Hoang, QQ; Johnson, SM; Park, Y; Ray, AM; Salim, N; Sivinski, J; Stevens, M; Washburn, A | 1 |
| Bédard, PJ; Berthiaume, L; Calon, F; Di Paolo, T; Hadj-Tahar, A; Julien, C; Julien, P; Rajput, AH | 1 |
| Luquin-Piudo, MR; Sanz, P | 1 |
3 other study(ies) available for levodopa and arachidonic acid
| Article | Year |
|---|---|
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
Topics: Biological Products; Chaperonin 10; Chaperonin 60; Escherichia coli; Humans; Inhibitory Concentration 50; Protein Folding; Rafoxanide; Salicylanilides; Suramin | 2019 |
Postmortem brain fatty acid profile of levodopa-treated Parkinson disease patients and parkinsonian monkeys.
Topics: Aged; Aged, 80 and over; Animals; Arachidonic Acid; Cerebral Cortex; Chromatography, Gas; Dietary Fats; Disease Models, Animal; Docosahexaenoic Acids; Dopamine Agents; Dyskinesia, Drug-Induced; Fatty Acids; Fatty Acids, Unsaturated; Female; Humans; Levodopa; Lipid Metabolism; Macaca fascicularis; Male; Neurons; Parkinson Disease; Parkinsonian Disorders; Postmortem Changes; Species Specificity | 2006 |
Dopamine receptors, motor responses, and dopaminergic agonists.
Topics: Adenylyl Cyclases; Antiparkinson Agents; Arachidonic Acid; Calcium Channels; Dopamine; Dopamine Agonists; GTP-Binding Proteins; Humans; Levodopa; Motor Activity; Parkinson Disease; Protein Isoforms; Receptors, Dopamine | 2011 |